Fingerprinting Single Protein Molecules for Biomarker Assisted Precision Medicine

Introduction

Protein molecule sensing techniques are currently hampered by detection limits and require large samples to achieve acceptable levels of sensitivity, bias, throughput, cost, and time to result. Leveraging findings from our NanoProt-ID (ADG ERC), in SM-ProTrack we will develop a novel single-molecule sensing method with unprecedented levels of detail and accuracy.

Technology Overview

This technology is based on the separation of molecules using silicon nano-channels on a chip, tracking of single molecules, and high-precision identification using AI algorithms. Thus, the technology allows detection of multiplexed, full-length single proteins, from extremely small sample volumes, in a low-cost, portable device.

Clinical Relevance

Here, to advance the clinical relevancy of the technology and build specific commercial value, we will apply it towards Age-related Macular Degeneration (AMD) sensing based on liquid biopsy. AMD represents 90% of cases of legal blindness globally, affecting approximately 200 million people’s quality of life.

Challenges in Current Methods

To date, a quantitative sensing of AMD biomarkers has not been possible due to the extremely small volumes of the clinical eye-derived aqueous humour (AH) sample and the low abundance of the AMD biomarkers.

Collaboration and Validation

In collaboration with a leading AMD ophthalmologist, SM-ProTrack will advance the technology to proof-of-principle validation, hence building a solid commercialization case while addressing an unmet global need.

Future Applications

SM-ProTrack will pave the way for a low-cost, highly sensitive technology for single protein molecule sensing that can provide rapid and accurate results from dilute and small clinical sample volumes with minimal biases. Validated in the field of AMD biomarkers, our technology can be further applied in many other liquid biopsy diagnostics fields.